FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3161660923> ?p ?o ?g. }

• W3161660923 endingPage "478" @default.
• W3161660923 startingPage "478" @default.
• W3161660923 abstract "Psoriasis is an immune-mediated dermatosis usually associated with comorbidities. Treatment varies from topicals to systemic drugs and data on susceptibility to viral infections in psoriatic patients are scarce. The objectives of this study were to analyze psoriatic patients on different therapies who were at risk for COVID-19 for seroprevalence of SARS-COV-2, pro-inflammatory cytokine profile, comorbidities and outcomes in order to unveil the immunological mechanisms involved in the anti-viral response in patients with psoriasis. Seventy-five patients with psoriasis were divided according to treatment: immunobiologics, methotrexate, topicals and acitretin. Twenty healthy controls were included. Plasma samples were collected for: IgG SARS-COV-2 (ELISA); IL-27, IL-29 and IL-18 (ELISA); and IL-1β, IL-17A, IL-6 and TNF (cytometric array). Seropositivity for SARS-COV-2 was detected in 24 out of 75 psoriasis patients and did not relate to COVID-19 symptoms and/or hospitalization, despite associated comorbidities. Psoriasis patients who were asymptomatic for SARS-COV-2 exhibited immune imbalance with high levels of IL-18, IL-17A and IL-6, and low levels of IL-27 compared to healthy controls. Psoriasis groups showed significant increased cytokine levels only in the group with immunobiologics. Despite immune deviations and lower IL-27, which has a potential antiviral impact, psoriatic patients did not exhibit complications related to COVID-19. An understanding of this kind of proinflammatory profile of psoriatic patients and of the lack of severe outcomes for COVID-19 is essential to establish novel therapeutic approaches and preventive measures, including with regard to the concomitance of viral infections." @default.
• W3161660923 created "2021-05-24" @default.
• W3161660923 creator A5002506097 @default.
• W3161660923 creator A5019049232 @default.
• W3161660923 creator A5024949965 @default.
• W3161660923 creator A5026093959 @default.
• W3161660923 creator A5045650277 @default.
• W3161660923 creator A5045814232 @default.
• W3161660923 creator A5047251283 @default.
• W3161660923 creator A5051352949 @default.
• W3161660923 creator A5065268311 @default.
• W3161660923 creator A5067750397 @default.
• W3161660923 creator A5075028994 @default.
• W3161660923 creator A5078256516 @default.
• W3161660923 creator A5080979879 @default.
• W3161660923 creator A5085843328 @default.
• W3161660923 creator A5086663167 @default.
• W3161660923 date "2021-05-10" @default.
• W3161660923 modified "2023-10-07" @default.
• W3161660923 title "Impact of Inflammatory Immune Dysfunction in Psoriasis Patients at Risk for COVID-19" @default.
• W3161660923 cites W2042514128 @default.
• W3161660923 cites W2093457571 @default.
• W3161660923 cites W2117288212 @default.
• W3161660923 cites W2143973423 @default.
• W3161660923 cites W2316963936 @default.
• W3161660923 cites W2324467793 @default.
• W3161660923 cites W2337186217 @default.
• W3161660923 cites W2343141742 @default.
• W3161660923 cites W2561759163 @default.
• W3161660923 cites W2754980733 @default.
• W3161660923 cites W2790176056 @default.
• W3161660923 cites W2890147164 @default.
• W3161660923 cites W2924895007 @default.
• W3161660923 cites W2964884877 @default.
• W3161660923 cites W3014519793 @default.
• W3161660923 cites W3014687026 @default.
• W3161660923 cites W3016722483 @default.
• W3161660923 cites W3020611303 @default.
• W3161660923 cites W3028355101 @default.
• W3161660923 cites W3028909758 @default.
• W3161660923 cites W3030331655 @default.
• W3161660923 cites W3032838347 @default.
• W3161660923 cites W3036377737 @default.
• W3161660923 cites W3040924909 @default.
• W3161660923 cites W3042065713 @default.
• W3161660923 cites W3048333079 @default.
• W3161660923 cites W3048594421 @default.
• W3161660923 cites W3080367034 @default.
• W3161660923 cites W3093149116 @default.
• W3161660923 doi "https://doi.org/10.3390/vaccines9050478" @default.
• W3161660923 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8151299" @default.
• W3161660923 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34068473" @default.
• W3161660923 hasPublicationYear "2021" @default.
• W3161660923 type Work @default.
• W3161660923 sameAs 3161660923 @default.
• W3161660923 citedByCount "6" @default.
• W3161660923 countsByYear W31616609232021 @default.
• W3161660923 countsByYear W31616609232022 @default.
• W3161660923 countsByYear W31616609232023 @default.
• W3161660923 crossrefType "journal-article" @default.
• W3161660923 hasAuthorship W3161660923A5002506097 @default.
• W3161660923 hasAuthorship W3161660923A5019049232 @default.
• W3161660923 hasAuthorship W3161660923A5024949965 @default.
• W3161660923 hasAuthorship W3161660923A5026093959 @default.
• W3161660923 hasAuthorship W3161660923A5045650277 @default.
• W3161660923 hasAuthorship W3161660923A5045814232 @default.
• W3161660923 hasAuthorship W3161660923A5047251283 @default.
• W3161660923 hasAuthorship W3161660923A5051352949 @default.
• W3161660923 hasAuthorship W3161660923A5065268311 @default.
• W3161660923 hasAuthorship W3161660923A5067750397 @default.
• W3161660923 hasAuthorship W3161660923A5075028994 @default.
• W3161660923 hasAuthorship W3161660923A5078256516 @default.
• W3161660923 hasAuthorship W3161660923A5080979879 @default.
• W3161660923 hasAuthorship W3161660923A5085843328 @default.
• W3161660923 hasAuthorship W3161660923A5086663167 @default.
• W3161660923 hasBestOaLocation W31616609231 @default.
• W3161660923 hasConcept C126322002 @default.
• W3161660923 hasConcept C16005928 @default.
• W3161660923 hasConcept C164027704 @default.
• W3161660923 hasConcept C203014093 @default.
• W3161660923 hasConcept C2776914184 @default.
• W3161660923 hasConcept C2777910003 @default.
• W3161660923 hasConcept C2780564577 @default.
• W3161660923 hasConcept C71924100 @default.
• W3161660923 hasConcept C8891405 @default.
• W3161660923 hasConceptScore W3161660923C126322002 @default.
• W3161660923 hasConceptScore W3161660923C16005928 @default.
• W3161660923 hasConceptScore W3161660923C164027704 @default.
• W3161660923 hasConceptScore W3161660923C203014093 @default.
• W3161660923 hasConceptScore W3161660923C2776914184 @default.
• W3161660923 hasConceptScore W3161660923C2777910003 @default.
• W3161660923 hasConceptScore W3161660923C2780564577 @default.
• W3161660923 hasConceptScore W3161660923C71924100 @default.
• W3161660923 hasConceptScore W3161660923C8891405 @default.
• W3161660923 hasIssue "5" @default.
• W3161660923 hasLocation W31616609231 @default.
• W3161660923 hasLocation W31616609232 @default.
• W3161660923 hasLocation W31616609233 @default.

• next